Impact assessment

Hereditary tyrosinaemia type 1 screening: impact assessments

Impact assessment and equality impact assessment on screening for hereditary tyrosinaemia type 1 in the NHS Newborn Blood Spot Screening Programme.

• From: Department of Health and Social Care
• Published: 1 March 2024

This was published under the 2022 to 2024 Sunak Conservative government

Applies to England

Documents

Impact assessment: screening for hereditary tyrosinaemia type 1 (HT1)

PDF, 648 KB, 45 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Equality impact assessment: screening for hereditary tyrosinaemia type 1 (HT1)

HTML

Details

The UK National Screening Committee (UK NSC) recommends offering screening for hereditary tyrosinaemia type 1 (HT1).

The impact assessment covers:

• the rationale for the intervention (screening for HT1)
• the evidence base
• a description and economic assessment of the policy options
• monetised and non-monetised costs and benefits of each option
• laboratory requirements
• a summary of the preferred option

The equality impact assessment covers:

• policy objectives
• who is affected
• the evidence considered
• engagement with stakeholders
• a summary of the analysis and potential impacts

Contact uknsc@dhsc.gov.uk for any queries on these publications, making sure you include the full title.

Published 1 March 2024